How Will the Market React to Assertio Holdings Inc (ASRT) Stock Getting a Neutral Rating

The market has been neutral on Assertio Holdings Inc (ASRT) stock recently. ASRT gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Assertio Holdings Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ASRT!

See Full ASRT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ASRT Stock Today?

Assertio Holdings Inc (ASRT) stock is trading at $1.18 as of 2:08 PM on Monday, Nov 27, a drop of -$0.04, or -3.28% from the previous closing price of $1.22. The stock has traded between $1.16 and $1.23 so far today. Volume today is less active than usual. So far 792,810 shares have traded compared to average volume of 1,786,977 shares. To see InvestorsObserver's Sentiment Score for Assertio Holdings Inc click here.

More About Assertio Holdings Inc

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. Click Here to get the full Stock Report for Assertio Holdings Inc stock.